We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Scapa Group Plc | LSE:SCPA | London | Ordinary Share | GB0007281198 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 214.50 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 214.50 | 215.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 214.50 | GBX |
Scapa (SCPA) Share Charts1 Year Scapa Chart |
|
1 Month Scapa Chart |
Intraday Scapa Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 22/4/2021 | 18:17 | Scapa onwards and upwards | 1,955 |
| 05/10/2006 | 15:18 | Scapa.......nobrainer or should I scarper? | 76 |
| 16/3/2006 | 13:43 | SCAPA upwards | 147 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 15/4/2021 08:37 by yertiz RNS suspending share pending announcement. Either the deal is off or another interested party joining the show? 215p is too cheap. |
Posted at 22/2/2021 17:19 by investor119 In response to the publication and posting of Scapa Group PLC’s Scheme Document in relation to the recommended cash offer of Scapa Group PLC (“Scapa”“Blackmoor Investment Partners invested in Scapa Group PLC in 2019 as an interesting transformation opportunity with strong intrinsic value. As a significant long-term shareholder, we continue to view Scapa as a valuable business that is in the early stages of a highly promising strategy. As a result, we believe this opportunistic bid from Schweitzer-Mauduit International wholly undervalues the business and we are implacably opposed to it. While this offer represents a low 18.6% premium to the pre-bid price, it only represents a 12.3% premium to the highest share price during the month before the bid, and a ca.22% discount to the price pre-COVID and pre-Industrial (now fixed) problems. At a fundamental level, the bid values the business at as little as nine times prospective EBITDA earnings while similar companies trade on multiples above 14 and up to 18 times. “We believe a number of other Scapa shareholders feel as we do, and we call on the Board to reconsider its support for this Offer and redouble their efforts to deliver better long-term value for shareholders and other stakeholders.” |
Posted at 20/2/2021 10:45 by techno20 SCM announced their 3rd qtr earnings earlier in the week. Didn’t give anything away on Scapa, but clearly still very much front of their minds;Dr. Kramer concluded, "As we enter 2021, we are encouraged by the underlying fundamentals of our business and in our end-markets. While we would typically provide Adjusted EPS guidance at this juncture, our offer to acquire Scapa Group Plc, a UK public company, is subject to the jurisdiction of the UK Takeover Code, under which we are restricted in our ability to disclose any material new information relating to SWM or Scapa, or the offer for Scapa that has not previously been announced to the market. We plan to issue specific financial guidance for 2021 upon closing of the Scapa transaction. However, excluding the pending acquisition, we fully expect to grow adjusted EPS this year. Directionally, we would expect some normalization in EP profits, after a particularly strong 2020, more towards our recent multiyear trend line, good top and bottom line organic growth in AMS, and another year of robust free cash flow. In summary, SWM is well-positioned for another strong year. Further, as stated in our Scapa offer announcement, we believe the acquisition would significantly expand our capabilities, complement our existing end-markets, and propel SWM toward $1.5 billion of annualized sales with an enhanced growth profile. We look forward to executing on our strategic priorities in 2021, investing for growth, and creating value for our employees, customers, and shareholders." Given the share price is still holding well above the offer price and they are clearly still committed, looks like they’ll need to increase. Suspect it won’t be too much longer before we get an announcement. |
Posted at 04/2/2021 14:51 by robow well the price is going up |
Posted at 27/1/2021 14:18 by marmar80 I sold Scapa earlier for 180 so of course regret my decision today, but want to share with you this what I posted on JLP board today.Not relevant to platinum (JLP) but need to share as a relevant to any takeover. Today saw an offer for entire Scapa for GBP400m+. That's a low offer, but Scapa's revenue is similar to Jubilee's. Scapa's profit is way way lower and there is a debt to pay. This way I can see Jubilee takeover for around GBP around 1b. Definitely not less than 400m and for sure not at mcap 250m as is now.Feel free to join Jubilee later as they are a very profitable company now and carry no debt. |
Posted at 27/1/2021 12:01 by pugugly pg - Depends partly if you are in profit or not - Gut feel suggests maybe sell part to lock in some profit/cut losses as over the current recommended bid price and gamble with the rest for a higher offer -v- a 5% odd lower cash pay without dealing costs further down the line (but DYOR no recommendation either way) |
Posted at 27/1/2021 11:09 by deanowls Maybe that explains the over offer price today? |
Posted at 14/10/2020 08:36 by robow Scapa is a value recovery play, says JefferiesChemicals group Scapa (SCPA), which specialises in chemicals for healthcare such as wound sealant, is a ‘value recovery play’, according to Jefferies. Analyst Kit Lee retained his retained his ‘buy’ recommendation and target price of 150p on the shares, which rose 8.4% to 133.8p yesterday after the company said half-year revenues would top expectations. ‘While second-half 2021 will likely still see impact from Covid-19, end-market demand is recovering in various segments and should normalise in full-year 2021/22,’ Lee said. ‘Longer term, we believe healthcare is well positioned to drive upside with the development pipeline and asset acquisitions. With shares trading at 11 times current year 2022 price-earnings, we view Scapa as a value recovery play.’ |
Posted at 19/8/2020 11:11 by discodave45 Hope this doesn't repeat June's share price profile. |
Posted at 29/7/2020 18:23 by discodave45 Just checked and issued shares have increased by about 25% since March 2015, FY year end eps in 2015 was 9p and the share price was circa £2 (PE 22). Recent prelims gave adjusted eps of 12.4p which normalised to 2015 issued share capital is equivalent to eps of about 16p (22 = £3.50), so the market appears to be suggesting a crash to circa 3p eps for 2020/21.......crazy! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
